TBA (last known deadline was March 6, 2012)
JDRF has made a commitment to play a pioneering role in the discovery and validation of biomarkers in Type 1 Diabetes (T1D). Identification and validation of new biomarkers [or standardization of existing biomarkers] is critical for the development of new T1D therapeutics and for appropriate staging of the disease. The ideal biomarker is one that can be measured in a minimally invasive way, can be measured repeatedly over time, identifies susceptibility to early stages of disease, is indicative of disease progress, or correlates well with response to therapy. The present call will focus on: 1) Biomarkers of Autoimmunity in Type 1 Diabetes 2) Biomarkers of Beta Cell Mass and Function